French urological device company deletes Europe market listing:
This article was originally published in Clinica
Executive Summary
An ongoing and "significant" decline in the liquidity of the ADSs of EDAP TMS has prompted the French producer of minimally invasive urological devices to seek delisting from Nasdaq Europe. The move, decided on February 11 and requested by the Vaulx-en-Velin company on February 28, will take place on April. The US Nasdaq listing will not be affected. CEO Eric Simon said that continued trading on the European Nasdaq did not add sufficient value for EDAP or its shareholders.
You may also be interested in...
Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion
Two Chairs, which uses algorithms to match the right therapists with patients, secured $72m in investment to expand its business.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.